A multicenter, open-label, follow-up trial evaluating the long-term safety of levetiracetam individualized dose from 1000 to 3000 mg/day (oral tablets of 500 mg b.i.d.), used as monotherapy in subjects (at least 16 years) suffering from epilepsy and coming from the N01061 or the N01093 trials.

Trial Profile

A multicenter, open-label, follow-up trial evaluating the long-term safety of levetiracetam individualized dose from 1000 to 3000 mg/day (oral tablets of 500 mg b.i.d.), used as monotherapy in subjects (at least 16 years) suffering from epilepsy and coming from the N01061 or the N01093 trials.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Levetiracetam (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors UCB Pharma Inc
  • Most Recent Events

    • 06 Jul 2007 Status changed from in progress to completed.
    • 14 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top